Merck 2017 forecast eases concerns over royalty payments, dollar

(Reuters) - Merck & Co Inc reported better-than-expected U.S. quarterly sales for its key cancer drug, Keytruda, and forecast largely in-line 2017 results, which some analysts said allayed concerns over the impact of a strong dollar and royalty payments.

Merck 2017 forecast eases concerns over royalty payments, dollar
Read More


Bagikan Berita Ini